Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the EU / 2026-525521-20-00
Authorised, not yet recruiting Phase I/II

The headache- and migraine-inducing effects of pitolisant in women with migraine without aura

2026-525521-20-00 · tracked via the Priya Life Science EU tracker
Sponsor
Syddansk Universitet (University of Southern Denmark)
Sponsor type
Educational Institution
Therapeutic area
Nervous System Diseases
Decision date
26/03/2026
Enrollment target
14
Sites
Denmark

Condition studied

Migraine without aura

Investigational medicinal product(s)

IBUPROFENWakix 18 mg film-coated tabletsSUMATRIPTANGELATIN

Every trial of Sumatriptan, Pitolisant and Ibuprofen across our registers →

Eligibility

Age group
18-64 years
Sex
Female

Primary endpoint

The occurrence of migraine-like attacks in pitolisant- and placebo-treated women with migraine without aura

Endpoint detail

Headache intensity over time, expressed as the area under the curve (AUC), following pitolisant and placebo administration in women with migraine without aura, The occurrence of any headache, irrespective of migraine criteria, following pitolisant and placebo administration

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525521-20-00 on CTIS ↗ ← All trials in the EU